This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Updated annually, our Private Markets Review offers the best of our research and insight into private equity, private real estate, and other private markets. Explore the findings from our most recent report and scroll for past years’ reports.
Approaching my first blogging anniversary, I am honored that Feedspot.com has named this one of the world's top 75 Bank Blogs. I'm glad to be in the top 75, and I hope, with your help as a blog follower, or even better if you link to this blog, to vault rapidly up the ladder. Let's quickly segue to my favorite topic these days, cybersecurity.
CAR T-Cell therapy, a new biologic therapy, is taking off. As companies continue to develop this new and promising therapy, patent litigation inevitably follows. CAR T-Cell therapy can be thought of as turbo-charging a patient’s own T-cells to treat cancer. At a high level, CAR T-Cell therapy works as follows: (1) a patient’s own T-cells are extracted and shipped to a laboratory, (2) scientists genetically engineer the T-cells to express a chimeric antigen receptor (CAR) that will re
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content